Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Part of Lymphoma

Subtypes of Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma 21 Follicular Lymphoma 6 Mantle Cell Lymphoma 2 Mycosis fungoides 2 Burkitt's lymphoma 1 Peripheral T-cell lymphoma 1 B-cell lymphomas 0

39 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Non-Hodgkin's Lymphoma

469 trials tracked for Non-Hodgkin's Lymphoma: 43 in phase 3 or 4 and 20 with published results. The most-cited published study has 728 citations.

469Trials tracked
43Phase 3 & 4
0Recruiting
20With published results
Phase distribution
Phase 4 7 Phase 3 36 Phase 2 332 Phase 1 73 Other / NA 21
  1. Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 728 cited
  2. Phase 3 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Completed · 587 cited
  3. Phase 3 A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Completed · 551 cited
  4. Phase 3 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma Completed · 525 cited
  5. Phase 3 A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) Completed · 344 cited
  6. Phase 3 Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Completed · 176 cited
Show 44 more trials
  1. Phase 3 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Completed · 150 cited
  2. Phase 3 PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Completed · 126 cited
  3. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 112 cited
  4. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 102 cited
  5. Phase 3 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab Completed · 65 cited
  6. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed · 59 cited
  7. Phase 3 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Completed · 32 cited
  8. Phase 3 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Completed · 21 cited
  9. Phase 3 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL Completed · 20 cited
  10. Phase 3 Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Completed · 18 cited
  11. Phase 3 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Completed · 11 cited
  12. Phase 3 Double Cord Versus Haploidentical (BMT CTN 1101) Completed · 10 cited
  13. Phase 3 A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment Completed · 5 cited
  14. Phase 4 A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) Completed · 1 cited
  15. Phase 4 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed
  16. Phase 4 Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) Completed
  17. Phase 4 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed
  18. Phase 4 A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma Completed
  19. Phase 4 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed
  20. Phase 4 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed
  21. Phase 3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed
  22. Phase 3 Zevalin-beam for Aggressive Lymphoma Completed
  23. Phase 3 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Completed
  24. Phase 3 Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A Completed
  25. Phase 3 A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma Completed
  26. Phase 3 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed
  27. Phase 3 Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed
  28. Phase 3 Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss Completed
  29. Phase 3 Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed
  30. Phase 3 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed
  31. Phase 3 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma Completed
  32. Phase 3 A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) Completed
  33. Phase 3 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Completed
  34. Phase 3 Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Completed
  35. Phase 3 A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma Completed
  36. Phase 3 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed
  37. Phase 3 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed
  38. Phase 2 Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Completed
  39. Phase 2 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Completed
  40. Phase 2 Autologous and Allogeneic Transplant for Relapsed Lymphoma Completed
  41. Phase 2 Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant Completed
  42. Phase 2 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Completed
  43. Phase 2 Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Completed
  44. Phase 2 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Completed

Showing the 50 most-cited and recently-updated of 469 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Non-Hodgkin's Lymphoma: what the trials found

Brentuximab vedotin has demonstrated significant efficacy in specific subsets of Non-Hodgkin's Lymphoma. In a Phase 3 trial, it showed an Objective Response Rate (ORR4) of 54.7% compared to 12.5% (p<0.001), with a corresponding increase in Complete Response (CR) rates of 17.2% vs 1.6% (p=0.0002) and Progression-Free Survival (PFS) of 16.7% vs 3.5% (p<0.001) 17. Additionally, a Phase 4 study confirmed an ORR of 60.0% for patients with CD30+ MF or pcALCL 10.

Ibrutinib showed significant improvements in Progression-Free Survival (PFS). In one trial, the Kaplan-Meier estimate at month 30 was 78.5% vs 31.1% (p<0.0001), and at month 48, it remained significantly higher at 74.0% vs 22.0% (p<0.0001). Notably, in a high-risk sub-population (del17p/TP53 mutation/Del 11q), the PFS was 82.4% vs 14.1% (p<0.0001) 18.

Obinutuzumab demonstrated significant improvements in Progression-Free Survival (PFS) as assessed by both Independent Review Committee (14.1% vs 29.2%, p<0.0001) and Investigator assessment (14.1% vs 25.8%, p<0.0001) 20.

Other established interventions include rituximab, which showed a progression-free survival rate of 24.0% 14 and was utilized in autologous transplantation protocols with high rates of platelet recovery (over 80%) 21. Bexarotene showed varied results for tumor response duration (99.4% vs 54.1%) and time to response (66.1% vs 117.0%) 12. Temsirolimus was associated with specific rates of infection-related and bleeding-related adverse events 13.

Recent results — preliminary, needs further review

  • Cyclophosphamide: Reported 0 or 1 instances of requiring immunosuppression at 2 years post-transplant 1.
  • Cyclosporine: Median time to onset of Grade II-IV aGVHD by day 100 was 34 days 2.
  • Lenalidomide: Showed progression-free survival rates of 66.7% to 100% at 2 years and 85.7% to 100% at 18 weeks 5.
  • AH-HA Tool in EPIC EHR: Significantly increased the proportion of patients reporting discussion of non-ideal or missing CVH topics (96.2% vs 52.2%, p<0.0001) 6.
  • Other recent trials include Mosunetuzumab 3, Fludarabine 4, Cholecalciferol 7, and a non-interventional study 8.

For the clinician treating this condition

  • Brentuximab vedotin is associated with significantly higher Objective Response Rates (ORR) and Progression-Free Survival (PFS) compared to standard controls in specific lymphoma types [17, 10].
  • Ibrutinib demonstrates significant superiority in Progression-Free Survival (PFS), particularly in high-risk sub-populations involving del17p/TP53 mutations or Del 11q 18.
  • Obinutuzumab provides statistically significant improvements in Progression-Free Survival (PFS) 20.
  • While Alisertib showed a statistically significant improvement in Overall Response Rate (ORR) 22, it did not reach statistical significance for Progression-Free Survival (PFS) or Overall Survival (OS).

AI synthesis of 17 cited trials, updated Jul 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients
Oncology RCT
Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients Nursing Program Reduces Fall Risk for Lymphoma Patients
This randomized controlled trial of 210 older adults with non-Hodgkin's lymphoma found that a multifaceted preventive nursing program signif…
A specialized nursing program significantly reduced falls and improved mobility for older adults undergoing chemotherapy for lymphoma.
Jul 20, 2026
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis
Oncology Meta-analysis
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis Gene Variants Linked to Higher Non-Hodgkin Lymphoma Risk
This meta-analysis of 53,864 cases and 60,448 controls found that certain IL-10 polymorphisms (rs1800890 and rs1800896) are associated with …
Certain IL-10 gene variants may slightly raise the risk of non-Hodgkin lymphoma, a large analysis finds.
Jul 4, 2026
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
Oncology Meta-analysis
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL CAR-T cell therapy shows improved survival for certain blood cancers
This meta-analysis of 2150 adult patients with relapsed or refractory diffuse large B-cell lymphoma found that CAR-T cell therapy significan…
New analysis shows CAR-T cell therapy significantly improves survival and response rates for patients with relapsed or refractory DLBCL.
Jul 3, 2026
Mogamulizumab monotherapy achieves 41.2% overall response rate in patients with cutaneous T-cell lymphomas
Dermatology Meta-analysis
Mogamulizumab monotherapy achieves 41.2% overall response rate in patients with cutaneous T-cell lymphomas Mogamulizumab Shows Meaningful Response in Cutaneous T-cell Lymphoma
This systematic review and meta-analysis of 453 patients evaluated mogamulizumab for Cutaneous T-cell Lymphomas, including Mycosis Fungoides…
New data shows mogamulizumab may be more effective for patients with Sézary Syndrome and blood involvement in certain skin cancers.
Jul 2, 2026
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL
Nutrition & Obesity Medicine Meta-analysis
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL Overweight status linked to better survival in certain lymphoma
A meta-analysis reveals that overweight status correlates with improved survival in DLBCL, while underweight status is linked to poorer clin…
Patients with diffuse large B-cell lymphoma who are overweight may have better survival outcomes than those who are underweight.
Frontiers Jun 24, 2026
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged
Allergy & Immunology Meta-analysis
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged New Treatment Options Show Promise for Specific Lymphoma Patients
This network meta-analysis of 1,016 treatment-naïve patients with MYC/BCL2 double-expressor DLBCL found that Pola-R-CHP significantly reduce…
A new drug combination may reduce the risk of disease progression in patients with a specific type of lymphoma.
Frontiers Jun 23, 2026
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma
Oncology RCT
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma Trial shows lenalidomide and rituximab for advanced follicular lymphoma
This Phase 3 randomized controlled trial of 1030 patients with previously untreated advanced follicular lymphoma found that the combination …
A large trial shows that a combination of two drugs can serve as an effective alternative to chemotherapy for patients with advanced follicu…
Blood Jun 20, 2026
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Oncology RCT
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Jun 20, 2026
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs
Allergy & Immunology Meta-analysis
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs Organ transplant recipients face higher risk of certain cancers
This meta-analysis of multi-centre cohort and registry-based studies indicates that solid organ transplant recipients experience significant…
People who receive heart or lung transplants face a significantly higher risk of dying from specific types of cancer.
Frontiers Jun 20, 2026
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Hematology Sys. Review
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Frontiers Jun 10, 2026
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Oncology Sys. Review
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Frontiers Jun 2, 2026
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Hematology Meta-analysis
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Jun 1, 2026

Research across Lymphoma

Related studies from across the Lymphoma family.

EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA
Radiology & Imaging Meta-analysis
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA Core Biopsy Shows Higher Yield for Lymphoma and Sarcoidosis
This meta-analysis of 1434 patients with mediastinal disorders found that EBUS-TBNB provides a significantly higher diagnostic yield for lym…
A core biopsy technique may provide more accurate results than standard needle aspiration for certain conditions like lymphoma and sarcoidos…
Jun 13, 2026
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy
Oncology Sys. Review
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy New treatments push Hodgkin lymphoma survival above 90%
This systematic review synthesizes outcomes in Hodgkin lymphoma, reporting 5-year survival exceeding 90% in early-stage patients and long-te…
For early-stage Hodgkin lymphoma, 5-year survival now exceeds 90%. Advanced disease remission tops 75%. But long-term toxicities remain a co…
Frontiers Jun 4, 2026
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Hematology Sys. Review
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Frontiers May 23, 2026
Systematic review of preclinical CBD effects in canine cancers
Cardiology Meta-analysis
Systematic review of preclinical CBD effects in canine cancers Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
Frontiers May 22, 2026
Systematic review and meta-analysis links benzene exposure to increased lymphoid neoplasm risk
Oncology Meta-analysis
Systematic review and meta-analysis links benzene exposure to increased lymphoid neoplasm risk Benzene exposure linked to higher lymphoid neoplasm risk in large review
This systematic review and meta-analysis evaluated 95 human studies on benzene exposure across occupational and environmental settings. The …
A review of 95 studies shows benzene exposure is associated with a significantly higher risk of lymphoid neoplasms, including Hodgkin lympho…
May 22, 2026
Network meta-analysis compares EBUS techniques for mediastinal lymphadenopathy diagnostic yield
Oncology Meta-analysis
Network meta-analysis compares EBUS techniques for mediastinal lymphadenopathy diagnostic yield Doctors find a better way to sample swollen lymph nodes safely
This systematic review and network meta-analysis evaluated diagnostic yield across EBUS techniques in 2357 patients with mediastinal and/or …
A new freezing biopsy technique finds the cause of swollen chest nodes more often than standard needles while staying safe for patients.
Apr 28, 2026
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
Allergy & Immunology Sys. Review
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Frontiers Apr 24, 2026
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma
Drug Pipeline Sys. Review
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma Can combining targeted drugs with CAR-T therapy help lymphoma patients who have run out of options?
This narrative review evaluates the potential of combining small molecule targeted drugs, specifically BTK and Bcl-2 inhibitors, with CAR-T …
Combining targeted drugs with CAR-T therapy may help lymphoma patients who have run out of options by improving treatment effectiveness and …
Frontiers Apr 18, 2026
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma
Oncology Cohort
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma Blood protein test may help predict severe side effects in lymphoma patients
A cohort study of 98 relapsed/refractory lymphoma patients at MD Anderson and Moffitt Cancer Centers found that a circulating protein signat…
A new blood test can spot lymphoma patients at high risk for severe immune reactions before dangerous side effects start.
medRxiv Apr 14, 2026

Questions about Non-Hodgkin's Lymphoma

What is the focus of current clinical trials for Non-Hodgkin's Lymphoma?

Current clinical trials for non-Hodgkin's lymphoma (NHL) focus heavily on early-phase development of CAR-T cell therapies and the evaluation of bispecific antibodies.

Full answer →

All Non-Hodgkin's Lymphoma Articles